T he lymphatic system comprises a highly organized network of vessels that is critical for immune cell trafficking, lipid transport, and tissue fluid homeostasis. Rather than being passive conduits, lymphatic vessels directly control local and distal inflammation.
1,2 Impairment of lymphatic endothelial cell (LEC) function exacerbates inflammation and is believed to contribute to the pathogenesis of common chronic inflammatory disorders, such as rheumatoid arthritis, Crohn disease, and psoriasis. [3] [4] [5] [6] Tumor necrosis factor (TNF), a key pleiotropic cytokine, is a major driver of inflammation in these pathologies. It has strong negative effects on the lymphatic vasculature in experimental arthritis and in patients with rheumatoid arthritis. 3, 6 Strategies targeted at reversing dysfunction of the lymphatic system in these pathological conditions hold promise for ameliorating or even promoting resolution of inflammatory states.
human coronary artery endothelial cells and restore and maintain vascular homeostasis. 10, 11 We wanted to find whether apoA-I can inhibit inflammation in the lymphatic vasculature. The results show that pretreatment of LECs with apoA-I attenuates the negative effect of TNF on their neovascularization capacity in an ABCA1-dependent manner. At the molecular level, this involved downregulation of TNF receptor-1 (TNF-R1) and maintenance of the expression of prospero-related homeobox gene-1 (Prox-1), a key transcriptional regulator of developmental and postnatal lymphangiogenesis. ApoA-I also restored normal lymphatic vasculature in human TNF transgenic (hTNFtg) mouse diaphragms. Collectively, these findings indicate that apoA-I reduces the negative effect of TNF on lymphatic neovascularization and may therefore promote the resolution of chronic inflammation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ApoA-I Reverses the TNF-Mediated Inhibition of LEC Tube Formation
The ability of LECs (characterized in Figure I in the onlineonly Data Supplement) to form tube-like structures in the presence of TNF was assessed by counting the number of branch points ( Figure 1A ). When LECs were incubated with TNF alone, the number of branch points was 87.1% lower than that in the control cells (P<0.0001). Preincubation of the LECs with apoA-I before incubation with TNF inhibited the TNF-mediated reduction in tube formation in a concentration-dependent manner (P<0.01). When the cells were preincubated with apoA-I at final concentrations of 0.1, 0.3, 0.6, and 1.2 mg/mL, the number of branch points progressively increased to 19.6±1.4%, 37.3±1.4%, 57.1±3.1%, and 97.1±2.2% of the control, respectively (P<0.0001 for TNF alone versus apoA-I at 0.3-1.2 mg/mL). When the LECs were incubated with apoA-I at a final concentration of 1.2 mg/mL and then incubated for an additional 6 hours in the absence of TNF, the number of branch points was comparable with that of the control cells ( Figure 1B ). Neither TNF alone nor incubation with apoA-I and TNF affected cell viability ( Figure  1C ). Collectively, these results indicate that apoA-I inhibits the adverse effects of TNF on the tube-forming capacity of LECs in a dose-dependent manner but does not directly promote tube formation.
ApoA-I Inhibits the Negative Effect of TNF on LEC Migration
The scratch assay was used to determine whether TNF affected the migratory capacity of LECs and, if so, whether this was modulated by apoA-I (Figure 2A and 2B) . When LECs were incubated with TNF, the number of cells that migrated across the scratch was 79.7±5.6% lower than that of control cells incubated in the absence of TNF (P<0.05). When the cells were preincubated with apoA-I at a final concentration of 1.2 mg/mL, the number of cells that migrated across the scratch increased to 146.9±28.8% of what was observed for the control cells (P<0.01 versus TNF alone). To exclude the possibility that the increased migration of the LECs that were preincubated with apoA-I was a reflection of LEC proliferation, incorporation of bromodeoxyuridine into the cells was quantified. These results established that neither TNF alone nor incubation with apoA-I and TNF affected bromodeoxyuridine incorporation into LECs ( Figure 2C ).
Collectively, these data demonstrate that preincubation with apoA-I reverses the inhibitory effect of TNF on the migratory capacity of LECs.
TNF-Mediated Inhibition of Thoracic Duct Lymphatic Sprouting Is Abrogated by ApoA-I
The beneficial effects of apoA-I were further validated in a thoracic duct (TD) ring system that recapitulates multiple aspects of lymphangiogenesis, including LEC spreading from a pre-existing vessel, LEC proliferation, and capillary formation. Control TD rings that were incubated for 14 days under hypoxic conditions exhibited a 46.1±12.4-fold increase in the outgrowth of capillary-like structures relative to baseline ( Figure 3A) . When the TD rings were incubated with TNF for 14 days, the lymphatic outgrowth of TD rings was almost completely abrogated (P<0.01; Figure 3A and 3B). Preincubation of the TD rings with apoA-I completely reversed the TNFmediated suppression of lymphatic outgrowth (P<0.01 versus TD rings incubated with TNF alone).
Lymphatic Protective Properties of ApoA-I Are Dependent on ABCA1
To determine whether the protective effects of apoA-I were dependent on ABCA1, TD rings were incubated for 1 hour with ABCA1-specific antibodies or an IgG isotype control antibody. The TD rings were then incubated for 24 hours with apoA-I and subsequently treated with TNF for 14 days. The use of blocking antibodies against ABCA1 has been shown previously to specifically abolish the anti-inflammatory effects of apoA-I. 12 The protective effects of apoA-I on lymphatic outgrowth in the presence of TNF were no longer apparent in the TD rings that were incubated with the anti-ABCA1 antibody. Lymphatic outgrowth was unaffected by incubation with the IgG isotype control (P<0.05; Figure 3C ). These results indicate that apoA-I abrogates the TNF-mediated suppression of the sprouting capacity of TD rings in an ABCA1-dependent manner. 
ApoA-I Maintains Prox-1 Expression in LECs in the Presence of TNF
Prox-1 is a key determinant of inflammation-driven lymphangiogenesis. The loss of the transcriptional activity of Prox-1 has previously been associated with suppression of LEC tube formation 13 and lymphatic sprouting of TD rings, 14 underscoring its fundamental role for determining the lymphatic phenotype. This was confirmed as shown in Figure  4A , which shows that Prox-1 mRNA levels are decreased 2.3-fold when LECs are incubated with TNF (P<0.05 compared with control). However, when LECs were preincubated with apoA-I before stimulation with TNF, Prox-1 mRNA levels did not decrease (P<0.05 compared with TNF alone). These results were confirmed by confocal microscopy ( Figure 4B ).
To validate these findings, we looked at 2 other LEC specific genes: lymphatic vessel endothelial receptor-1 (Lyve-1) and podoplanin. Lyve-1 mRNA levels were reduced 34.1-fold when LECs were incubated with TNF alone ( Figure 4A ; P<0.001 versus control). This inhibitory effect was partly reversed in LECs that were preincubated with apoA-I, with Lyve-1 mRNA levels being restored to 45.2±14.8% of that in control cells (P<0.05; Figure 4A ). Podoplanin mRNA levels were increased by 1.9-fold and 1.5-fold in LECs that were preincubated with apoA-I compared with control cells (P<0.01) and LECs incubated with TNF alone (P<0.05), respectively ( Figure 4A ). ApoA-I, by contrast, did not affect the transcription of other genes involved in lymphangiogenesis, such as Forkhead box protein C2, GATA-binding protein 2, neuropilin-2, vascular endothelial growth factor receptor 3, and notch ligand δ-like ligand 4 ( Figure IIA in the online-only Data Supplement). As crosstalk has been reported between the vascular endothelial growth factor family and the Notch pathway in the regulation of lymphangiogenesis, 15 expression of vascular endothelial growth factor receptor 3 and notch ligand δ-like ligand 4 was assessed by Western blotting ( Figure IIB and IIC in the online-only Data Supplement). There was no difference in notch ligand δ-like ligand 4 or vascular endothelial growth factor receptor 3 protein levels between LECs that were preincubated with apoA-I and TNF and those that were incubated with TNF alone.
ApoA-I Attenuates the Effects of TNF and Decreases
TNF-R1 mRNA Levels in LECs
To determine whether apoA-I conserves Prox-1 expression and LEC function in the presence of TNF directly or by limiting TNF bioactivity, LECs were incubated for 24 hours with increasing amounts of apoA-I before quantifying Prox-1 mRNA levels. These results established that apoA-I does not directly affect the expression of Prox-1 ( Figure III in the online-only Data Supplement). We then wanted to find whether the ability of apoA-I to limit the bioactivity of TNF reflected reduced the expression of the endothelial receptor TNF-R1. 16, 17 TNF-R1 mRNA levels in LECs were not affected by incubation with TNF alone ( Figure 5A ). However, when the LECs were preincubated with apoA-I before activation with TNF, TNF-R1 mRNA levels were 2.3-fold lower than those in control cells (P<0.01) and 1.8-fold lower than those in cells that were incubated with TNF alone (P<0.05; Figure 5A ). This result was confirmed by Western blotting. Compared with cells that were incubated with TNF alone, TNF-R1 protein expression was decreased 1.9-fold in LECs that had been preincubated with apoA-I (P<0.05; Figure 5B and 5C). As whole-cell lysates were used for these experiments, this result reflects the membrane pool of TNF-R1 that dictates cell sensitivity to TNF.
Preincubation with apoA-I also decreased mRNA levels of TNF-R-associated factor 2, an adaptor protein that is downstream of TNF-R1, by 2.9-fold and 2.2-fold relative to control cells (P<0.01) and LECs that were incubated with TNF alone (P<0.05), respectively ( Figure 5A ). ApoA-I, by contrast, did not affect the transcription of other genes, such as receptorinteracting protein-1, an adaptor kinase that is crucial to TNF-R1 signaling, or the nuclear factor-κB inhibitor, A20 ( Figure  5A ). Compared with cells that were incubated with TNF alone, p38 mitogen-activated protein kinase (MAPK) phosphorylation was decreased 1.9-fold in LECs that were preincubated with apoA-I and then incubated with TNF (P<0.05; Figure  5D and 5E). Taken together, these results are consistent with apoA-I inhibiting the detrimental effects of TNF on LECs by decreasing TNF-R1 expression and signaling.
Additional experiments were carried out to ascertain whether preincubation with apoA-I lowers TNF-R1 expression and signaling before stimulation with TNF. These results indicated that 24 hours of preincubation with apoA-I in the absence of TNF did not affect TNF-RI mRNA and protein expression (Fig. IVA-IVC in the online-only Data Supplement). Similarly, TNF-R-associated factor 2, A20, and receptor-interacting protein-1 mRNA levels were unaltered by incubation of LECs with apoA-I alone ( Figure IVA in the online-only Data Supplement). These results indicate that the apoA-I-mediated reduction in TNF-R1 expression and activity is apparent only in LECs that have been stimulated with TNF.
Preincubation With ApoA-I Increases TNF-α-Converting Enzyme Expression
A potential explanation for the reduced TNF-R1 expression involves the shedding of TNF-R1 from the cell surface through proteolytic cleavage by TNF-α-converting enzyme (TACE). This sheddase regulates cellular responsiveness to TNF by releasing soluble TNF-R1 from the cell surface, which inactivates TNF. 17 The possibility that TACE-mediated cleavage was responsible for the reduced TNF-R1 expression was addressed by using flow cytometry to quantify TACE expression in LECs. After preincubation with apoA-I, the number of TACE-expressing LECs was increased by 1.4-fold relative to LECs that were incubated with TNF alone (P<0.05; Figure V in the online-only Data Supplement). Given the close correlation between the surface protein expression of TACE and its cleaving activity, 18 this result is consistent with increased TACE activity enhancing the shedding of TNF-R1 and thus reducing cell surface TNF-R1 levels.
ApoA-I Restores a Normal Lymphatic Phenotype in hTNFtg Mouse Diaphragms
ApoA-I or phosphate-buffered saline was administered intraperitoneally 3× a week for 2 weeks into 6-week-old hTNFtg mice. Compared with littermate controls, the density of the lymphatic system in the diaphragms of the hTNFtg mice that received phosphate-buffered saline decreased (P<0.001), with fewer branch points (P<0.001) and blind-ended sacs (P<0.05; Figure 6A and 6B). The lymphatics in the hTNFtg mice were also smaller in diameter (P<0.05) than those of their littermate controls ( Figure 6C ). By contrast, a normal lymphatic phenotype, with morphological features similar to those of the control animals, was observed when the hTNFtg mice were treated with apoA-I (Figure 6A-6C) .
Discussion
This study uncovers a novel function of apoA-I: the restoration of the neovascularization capacity of lymphatic endothelium in the presence of TNF, the cytokine that is regarded as the major driver of lymphatic dysfunction in chronic inflammatory disorders. The results show that the protective effect of apoA-I is ABCA1 dependent. ApoA-I also reduced TNF-R1 signaling and conserved Prox-1 expression in LECs. These results were further corroborated in hTNFtg mice, 3, 6, 19 where the phenotype of the lymphatic vasculature of the diaphragm was normalized by apoA-I treatment. This suggests that apoA-I may regulate protective molecular pathways in lymphatic endothelium, and therefore, it is a potential therapeutic target with the capacity to improve lymphatic function and promote resolution of acute and chronic inflammatory states.
Inflammatory lymphangiogenesis is a dynamic process, featuring accelerated neoformation of lymphatic vessels to compensate for the increased amounts of extravasated tissue fluid and immune cell trafficking. Perturbation of this tightly regulated process has been reported to exacerbate inflammation in chronic inflammatory disorders, including rheumatoid arthritis, experimental arthritis, psoriasis, and Crohn disease.
3-5,20-22 TNF is involved in the pathogenesis of all of these disorders. The current findings showing that TNF inhibits key LEC functions, including tube formation, migratory capacity, and lymphatic sprouting, confirm previous reports that demonstrate the overt anti-lymphatic effects of TNF. TNF has been reported to impair capillary tube formation and barrier function in mouse and human LECs. 23 Intradermal administration of TNF in mice also results in an acute and systemic deterioration of lymphatic propulsion. 24 In addition, hTNFtg mice, a model of chronic inflammatory arthritis, exhibit decreased lymph flow from the joints compared with wild-type littermates. 6 Finally, TNF blockade in patients with rheumatoid arthritis and in experimental arthritis has been shown to promote lymphatic vessel formation and the resolution of chronic synovial inflammation.
The current report provides the first evidence that apoA-I protects LECs from the negative effects of TNF on lymphangiogenesis in several in vitro models and in hTNFtg mice. The results show that preincubation with apoA-I restores the tube-forming capacity of LECs in the presence of TNF in a dose-dependent manner, as well as the migratory and sprouting capacity of LECs and TD rings, respectively.
Rather than having a direct effect, apoA-I most likely overcame the negative effects of TNF by activating ≥1 signal transduction pathways in the LECs. This possibility was strengthened by showing that preincubation of LECs with apoA-I conserved the expression of Prox-1 in the presence of TNF. Prox-1 function is essential for inflammatory lymphangiogenesis 1 and is regulated by hypoxia-responsive genes that promote cell survival and proliferation, including hypoxiainducible factor-α and hypoxia-inducible factor-2α 25 as well as interleukin-3, 26 interleukin-7, 27 and the JAK2/STAT3 pathway. Moreover, the Kaposi sarcoma herpes virus depends on the JAK2/STAT3 pathway for Prox-1-mediated lymphatic reprogramming of ECs. 28 On the other hand, the loss of Prox-1 activity results in defective lymphangiogenesis. 13, 14 In a murine contact hypersensitivity model, downregulation of Prox-1 is inversely correlated with local TNF and interferon-γ production. 29 Furthermore, mice heterozygous for a mutation that inactivates Prox-1 exhibit features of leaky lymphatic vessels and are prone to develop obesity and inflammation. 30 The present report is consistent with these findings and further show that apoA-I prevents the TNF-mediated downregulation of Prox-1 expression in LECs in response to TNF.
ApoA-I may have conserved Prox-1 expression by 2 potential mechanisms: (1) limiting TNF-R1 signaling and (2) activation of the JAK2/STAT3 signaling pathway. 31 In doing so, apoA-I sustained lymphatic neovascularization in the presence of TNF. The present results are consistent with preincubation of LECs with apoA-I before TNF treatment reducing total TNF-R1 expression, including the receptor molecules at the cell surface, which confer cellular sensitivity to TNF, and in the Golgi, which is responsible for replenishing cell surface TNF-R1 levels. 17 Several lines of evidence were consistent with reduced TNF-R1 signaling in LECs that were preincubated with apoA-I. These include reduced TNF-R-associated factor 2 mRNA levels, reduced phosphorylation of p38 MAPK, and partial recovery of Lyve-1 expression. 32 The partial recovery of LYVE-1 expression in LECs preincubated with apoA-I is most likely because of reduced sensitivity of the cells to TNF, which reversibly downregulates the membrane expression of LYVE-1. This is also in line with the reduced TRAF2 mRNA levels ( Figure 5A ) and lower phosphorylation of p38 MAPK ( Figure 5D and 5E). Given the inverse correlation between Prox-1 expression in inflamed lymphatic endothelium and local TNF production, 29 it is also conceivable that decreased TNF-R1 signaling as a consequence of apoA-I pretreatment may have resulted in conservation of Prox-1 expression.
It is also possible that the reduced TNF-R1 expression in LECs preincubated with apoA-I is a reflection of enhanced activation of TACE 18 and increased shedding of TNF-R1 from the cell surface. 33 The integrity of lipid rafts and caveolae, where TACE and TNF-R1 are sequestered in the cell membrane, is critical for efficient TNF-R1 shedding. 34 Disruption of these domains either by incubation with methyl-β-cyclodextrin or by silencing of caveolin-1 has been shown to attenuate the TNF-R1-membrane shedding. 34 Through interaction with caveolin-1, apoA-I may stabilize lipid rafts and promote TACE-mediated cleavage of TNF-R1. 35, 36 The observation that apoA-I reduces TNF-R1 signaling only after stimulating LECs with TNF favors the hypothesis that apoA-I enhances the TNF-induced increase in TACE activity without affecting TNF-R1 expression directly. The decreased TNF-R1 mRNA levels in LECs preincubated with apoA-I ( Figure 5A ) suggest that reduced protein synthesis may also have contributed to the reduction in TNF-R1 cell surface protein levels. . ApoA-I treatment restores a normal lymphatic phenotype in human tumor necrosis factor transgenic (hTNFtg) mouse diaphragms. Six-week-old hTNFtg mice were injected intraperitoneally 3× a week for 2 weeks (6 injections in total) with 1.2 mg/kg of apoA-I or phosphate-buffered saline (PBS). The central tendon side of the diaphragm was used for whole-mount immunofluorescence. For morphological analysis, lymphatic vessels were detected with an anti-lymphatic vessel endothelial receptor-1 antibody. The diaphragms were mounted in DAPI-containing mounting media and imaged using confocal microscopy. A, Representative images of the diaphragm lymphatic system. B and C, Systematic quantification of the lymphatics. Values represent the mean±SEM of at least 3 separate experiments. *P<0.05 vs control; ***P<0.001 vs control; *P<0.05 vs PBS; **P<0.01 vs PBS; ***P<0.001 vs PBS.
Another mechanism by which apoA-I may have conserved Prox-1 expression is via the JAK2/STAT3 axis. Previous studies in macrophages have shown that apoA-I can limit responsiveness to lipopolysaccharide via the ABCA1/JAK2/ STAT3 pathway. 37 Further investigation of the contribution of ABCA1, and the downstream JAK2/STAT3 signaling pathway, to the protective effects of apoA-I was hindered by the low ABCA1 protein levels in cultured LECs.
As apoA-I did not affect other signaling pathways that control lymphangiogenesis, such as vascular endothelial growth factor receptor 3 and notch ligand δ-like ligand 4 ( Figure II in the online-only Data Supplement), it is possible that alternative mechanisms, including the fibroblast growth factor 2-Lyve1 axis, might be involved. 38 Furthermore, as apoA-I alone did not increase Prox-1 expression or stimulate tube formation, it follows that this apolipoprotein is unable to directly maintain Prox-1 expression or mediate tubulogenesis in the presence of TNF.
In conclusion, this study identifies apoA-I as a critical regulator of lymphatic vascular homeostasis during inflammation and provides the first proof-of-concept evidence that HDL-based therapeutic strategies may increase lymphatic neovascularization and function in chronic inflammatory disorders and reverse chronic inflammation. The results also indicate that lymphatic vascular dysfunction can be reversed by apoA-I in an inflammatory setting. When taken together, these findings represent a powerful stimulus for ongoing efforts targeting HDL in chronic inflammatory disorders in addition to the current therapeutic arsenal of anti-inflammatory drugs.
